C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

By: Investing.com

Sep 10 2024
1
351 Views

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Abstract Released Today Highlights Favorable Safety Profile and Early Evidence of Monotherapy Anti-Tumor Activity
Investor Webcast to be Held Friday, September 13, 2024 at 12:00 pm ET
WATERTOWN, Ma… [+5444 chars]

Pharmacide; Killing Us Softly

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Survival essentials: Essential items to include in your stockpile before SHTF

First mpox vaccines arrive as Congo grapples with fast-growing outbreak

New technique to explore oceanic microbes

This Canadian company can now export psychedelics to treat mental health disorders

Innovus Pharmaceuticals (OTCMKTS:INNVD) Trading Up 143.9%

Helping Redefine Medicine: AJNA BioSciences' Path For FDA-Approved Plant Medicines

Targeted cancer therapies: Getting radioactive atoms to accumulate in tumors

Extreme weather 101: Your guide to staying prepared and informed

Respected Comrade Kim Jong Un Clarifies in His Speech Stand of Party and Government on Repairing Flood Damage and Consoles Flood Victims

Share this page

Guest Posts by Easy Branches

anchor links ads by Easy Branches

C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024

Related